title: Advances in the management of PML: focus on natalizumab.
abstract: Progressive multifocal leukoencephalopathy (PML), a rare opportunistic infection of the central nervous system, occurs mainly in the setting of broad-based and selective immunosuppression. The immunomodulatory agent most often implicated in the development of PML is the monoclonal antibody natalizumab. Management of PML begins with risk stratification. Factors that predict the risk of PML are JC virus (JCV) antibody status, history of chemotherapy use, and cumulative exposure to natalizumab. The risk of natalizumab-related PML increases up to a duration of 36 months of therapy, after which the risk appears to level off. If suspicious for PML, the use of a sensitive JCV polymerase chain reaction assay permits early diagnosis. Immune reconstitution represents the mainstay of treatment for PML. With rapid reversal of immunosuppression followed by immunologic recovery, almost all patients suffer clinical deterioration termed immune reconstitution inflammatory syndrome (IRIS). High-dose corticosteroids are often recommended if a clinical and imaging syndrome resembling IRIS develops after immune restoration.
authors: Mellen Center for Multiple Sclerosis, Cleveland Clinic, 9500 Euclid Ave., U10, Cleveland, OH 44195, USA. foxr@ccf.org
authors: Robert
authors: R
authors: Fox
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000914:Antibodies, Viral / Q000097:blood*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007577:JC Virus / Q000276:immunology; D007968:Leukoencephalopathy, Progressive Multifocal / Q000188:drug therapy / Q000276:immunology / Q000821:virology*; D000069442:Natalizumab; D013997:Time Factors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000914:Antibodies, Viral; D007166:Immunosuppressive Agents; D000069442:Natalizumab